Jiangsu Recbio Technology Co., Ltd. (stock code: 2179) is scheduled to convene its first extraordinary general meeting of 2025 on December 19, 2025 at 10:00 a.m., at Conference Room, 3/F, Building G29, Standard Plant, China Medical City Phase 6, Medical High-tech District, Taizhou City, Jiangsu Province. Shareholders will review multiple proposals, including the abolition of the Supervisory Board, amendments to the Articles of Association and related attachments, the election of new directors, amendments to the Rules for the Management of Connected Transactions, and amendments to the Working Procedures of the Independent Non-executive Directors.
Key agenda items include the proposed abolishment of the Supervisory Board, with corresponding revisions to the Company’s governance framework, and the proposed election of three directors: one non-executive director (Xu Haoyu) and two executive directors (Wei Qifang and Wang Jing). The meeting will further consider amendments to the Company’s principal administrative documents to align with updated statutory requirements and optimize internal governance structures.
According to the announcement, valid forms of proxy must be lodged at least 24 hours before the meeting, and only holders of H Shares registered before December 19, 2025 will be entitled to vote. The Company will disclose the voting results promptly after the meeting in accordance with relevant regulations.
Comments